Biotech CROs Take Center Stage in Recent Deals
Thursday, May 6th, 2010
Global contract research services firm Charles River Laboratories (CRL) is expanding its presence in China with the acquisition of WuXi PharmaTech (WX), a major drug research and development outsourcing company with expertise in discovery chemistry and operations in both China and the United States. The $1.6 billion cash and stock deal will expand the global reach and growth opportunities for both companies.
“This transaction revolutionizes the contract research landscape by creating the only global contract research organization, or CRO, to offer fully integrated research and drug development services from molecule creation to first-in-human testing,” said James C. Foster, Chairman, President and Chief Executive Officer of Charles River
Tweet this!



